Senior Scientist/Senior Staff Physician, Princess Margaret Hospital, and Professor of Medicine, University of Toronto, Canada
David Hedley completed his higher specialist training in medical oncology, combined with a graduate program in tumour immunology, at the Royal Marsden Hospital, University of London. He was junior faculty at the University of Sydney, 1981-89 where he was responsible for the development of flow cytometry applications to cancer biology, including the technique for DNA content analysis using paraffin-embedded tissue that played a major role in the early development of clinical flow cytometry. Since 1990 he has been Senior Scientist/Senior Staff Physician at the Princess Margaret Hospital, and Professor of Medicine at the University of Toronto, Canada, with a major focus on pancreatic cancer. His laboratory makes extensive use of patient-derived xenografts that recapitulate the clinical spectrum of the disease, and develops flow cytometry techniques to study complex biological processes linked to experimental treatment development and early phase clinical trials. In 2015 Dr Hedley received the International Society for the Advancement of Cytometry’s Fulwyler Award for innovative excellence in flow cytometry.
Senior Technician, University of Toronto, Canada
Sue Chow graduated in molecular biology from the University of Toronto, and developed a specialist interest in flow cytometry, joining David Hedley’s lab as senior technician in 1990. David and Sue have published extensively in the area of flow cytometry applications, including the measurement of lipid peroxidation, antioxidant regulation, signal transduction analysis, cell cycle regulation, and epigenetic targeting. For the past 14 years they have been teaching the intensive annual flow cytometry research methods course that alternates between the University of New Mexico and Bowdoin College ME, and many international workshops.
Vice President, Immunology - Caprion Biosciences
Virginia Litwin is a thought-leader in analytical method validation and standardization for flow cytometry. “Cytometry from Bench-to-Bedside” has been the focus of her professional activities since 1999 when she started working in translational medicine at Bristol-Myers Squibb. She co-founded the Flow Cytometry APC within AAPS. This group published the first papers on flow cytometry method and instrument validation which Virginia was invited to present at the FDA Workshop on Clinical Flow Cytometry in 2013. Virginia is the chair of the Document Development Committee for the CLSI Guideline, H62- Validation of Assays Performed by Flow Cytometry. She is a councilor for ISAC and ICCS. Virginia edited the book, Flow Cytometry in Drug Discovery and Development (Wiley-Blackwell), a Special Issue of the Journal of Immunology Methods on Flow Cytometry Biomarkers and Translational Medicine, and a Special Issue of Cytometry Part B dedicated to Receptor Occupancy. After obtaining a Ph.D. from the University of Iowa, Virginia joined Lewis Lanier at DNAX as a post-doc. She was the scientific leader for flow cytometry at Covance from 2010 to 2017 and was also the first recipient of the Covance Science and Technology Award. Recently, she joined Caprion Biosciences as Vice President, Immunology.
Professor Oncology and Director Department of Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center
Paul Wallace, Professor Oncology and Director Department of Flow & Image Cytometry at Roswell Park Comprehensive Cancer Center, is recognized for his expertise in clinical flow cytometry with a strong background in immunology and research interests in antigen processing and presentation. He is President of the International Society for the Advancement of Cytometry (ISAC) and a past Councilor of the International Clinical Cytometry Society (ICCS). Flow and Image Cytometry at Roswell Park offers a strong combination of clinical and research missions and under Dr. Wallace’s direction actively works to build translational synergies between them. The clinical laboratory is focused on the diagnosis and monitoring of patients with leukemia and lymphoma with a recent emphasis on minimal residual disease. Before joining Roswell Park, Dr. Wallace was an Assistant Professor of Immunology at Dartmouth Medical School, Lebaonon, NH (1993-2003); a cofounder of Zynaxis Cell Science, Inc., Malvern PA (1988-1991) the company that developed the PKH tracking dyes, and supervisor of Microbiology, Immunology, Serology, and Flow Cytometry at SmithKline Clinical Laboratories. He obtained his PhD from the Medical College of Pennsylvania in 1993 and his Masters from Idaho State University in 1979.
Tracking cell proliferation
The number of fluorescent dyes commercially available for cell tracking, and the subset useful for proliferation monitoring continues to expand rapidly. Dyes of one class, referred to as "protein dyes", react with proteins to form a covalent bond. Dyes of the other class, referred to as "membrane dyes", stably intercalate into the lipid bilayer of cell membranes via strong hydrophobic associations. They can be used to label almost any cell and have enabled biologists monitor a wide variety of tumor and immune cell functions including: migration and adhesion; proliferation of stem and progenitor cells; differentiation and growth control; mechanisms of antigen presentation; and interactions of effector and regulatory cells with each other and with tumor cells. Participants of this lab will learn how to stain cells with both protein and lipophilic dyes and how to correctly analyze and interpret the resulting data.
mRNA Cytometry. Until recently our ability to detect mRNA gene transcripts by flow cytometry has been limited. The relatively new branched DNA technique amplifies signal from a single mRNA species several thousand fold permitting the detection of as few as 5 copies of mRNA within a cell. The technique is compatible with antibody-based targeting allowing mRNA detection within specific subpopulations within a mixed population of cells. Examples in this lab will emphasize monocyte activation with LPS and the kinetics of cytokine mRNA and protein expression.
- Tario JD, Jr., Conway AN, Muirhead KA, Wallace PK. Monitoring Cell Proliferation by Dye Dilution: Considerations for Probe Selection. Methods Mol Biol 2018;1678:249-299.
- Soh KT, Wallace PK. RNA Flow Cytometry Using the Branched DNA Technique. Methods Mol Biol 2018;1678:49-77.
- Soh KT, Tario JD, Jr., Colligan S, Maguire O, Pan D, Minderman H, Wallace PK. Simultaneous, Single-Cell Measurement of Messenger RNA, Cell Surface Proteins, and Intracellular Proteins. Curr Protoc Cytom 2016;75:7 45 1-7 45 33.
- Tario JD, Jr., Humphrey K, Bantly AD, Muirhead KA, Moore JS, Wallace PK. Optimized Staining and Proliferation Modeling Methods for Cell Division Monitoring using Cell Tracking Dyes. J Vis Exp 2012.
- Tario JD, Jr., Muirhead KA, Pan D, Munson ME, Wallace PK. Tracking immune cell proliferation and cytotoxic potential using flow cytometry. In: Hawley TS, Hawley RG, editors. Methods Mol Biol. Volume 699. New York: Humana Press; 2011. p 119-164.
Associate Director, Biosciences Division, Thermo Fisher Scientific
Jolene Bradford is an Associate Director, Biosciences Division of Thermo Fisher Scientific located in Eugene, Oregon, USA. Joining the original Molecular Probes Labeling and Detection Technologies in 2001, Jolene has developed numerous new reagents and assays for the flow cytometry platform, and has several patents awarded. Well versed in fluorescent assays, Jolene has also been involved in developing acoustic cytometry and instrumentation, and consults on applications. Prior to joining Molecular Probes, Jolene performed clinical laboratory testing as a specialist in hematology and flow cytometry.
Pathologist, St Vincent's Hospital, and Garvan Institute, Sydney
Bill Sewell works as a pathologist at St Vincent’s Hospital Sydney, where he has extensive experience in clinical flow cytometry, especially for blood cancers. He has a keen interest in education, and has recently served as RCPA Chief Examiner in Immunopathology. He also works for the University of NSW where he teaches immunology and pathology. He has an appointment to the Garvan Institute and has a research interest in the immunological mechanisms of allergic disease.
Translational Oncology, University of Western Australia
Kathy Fuller has extensive experience in the development and use of flow cytometry protocols for cell analysis across a wide range of research areas including plant, marine and mammalian biology. Her previous research includes development of a high throughput plant ploidy screening protocol for plant breeding, development of an accurate method for enumeration of neurons in shark brains, and the development and validation of the Sperm Chromatin Structure Assay (SCSA) for routine diagnostic use by Western Australian embryology clinics. Kathy’s current research focus is Translational Oncology where she is developing imaging cytometry protocols for the analysis of haematological malignancies and minimal residual disease. This includes the first immuno-flowFISH protocol for combined immunophenotype-genotype analysis on the AMNIS ISXmkII (Cytometry Part A, 2016; METHODS, 2018) for which she was awarded the ANSTO 2018 Eureka Prize for Innovative Use of Technology.
QIMR Berghofer Medical Research Institute
Ashraful Haque completed his BA(Hons) in Natural Sciences at Cambridge University, UK (1997), followed by a PhD (2002) in microbial biochemistry (Salmonella pathogenesis) with Prof. Gordon Dougan FRS at Imperial College, London. After a first post-doctoral research position at the London School of Hygiene & Tropical Medicine, where he examined host immune responses during gram-negative bacterial infection, he moved to QIMR Berghofer in Brisbane, Australia, in 2006, to study T cell responses during parasitic infection. He has been funded by a Career Development Fellowship and Project Grants from the Australian National Health & Medical Research Council (NHMRC) and the Australian Research Council (ARC) to examine host immune responses during malaria. His research first defined an immune-suppressive role for Type I IFN-signalling in malaria. His current focus is to explore T-cell differentiation and blood-stage parasite responses during malaria using single-cell genomics technologies. He is an Associate Professor at the University of Queensland, and an adjunct Associate Professor at the Queensland Institute of Technology.
Cytometry, Imaging and IT Manager, Centenary Institute and Technical Director, Sydney Cytometry Core Research Facility
Adrian Smith has been the manager of the Cytometry and Imaging Facility at the Centenary Institute since 2004. He has overseen the growth of the facility from three flow cytometers in 2004 to now include over thirty instruments including a range of advanced optical microscopes and image cytometers, along with flow cytometers and cell sorters - including the world's first 10 laser analyser and first 10 laser cell sorter - and, most recently, Australia’s first mass cytometers that operate in both suspension and imaging modes. The cytometric capabilities are operated as the Sydney Cytometry Core Research Facility - a joint of initiative of Centenary and the University of Sydney - of which Adrian serves at the Technical Director. Adrian was the president of the Australasian Cytometry Society (ACS) (formerly the Australasian Flow Cytometry Group (AFCG)) from December 2010 to November 2014 and member of the Council of the International Society for the Advancement of Cytometry from 2014 to 2018. He continues to serve on various task forces and committees of these organisations, including as the chair of the ISAC Shared Resource Laboratories Emerging Leader Program Committee. Adrian teaches imaging and cytometry on a regular basis to both researchers and technical staff and he has presented workshop and tutorials for many groups including CSIRO, AFCG/ACS, QIMR, ASI, ISCT and ISAC (CYTO conference). He has also trained several core facility staff who are now managing their own facilities. Adrian started in flow cytometry over 20 years ago and his PhD in Immunology (peripheral CD4 T Cell responses) included more hours in front of a flow cytometer than he cares to (or can) remember. When he is not stuck behind a computer, looking down a microscope or sitting in front of cytometer he can be found with a camera in hand chasing the perfect shot.
Flow Cytometry and Imaging Facility, QIMR Berghofer Medical Research Institute
Nigel Waterhouse graduated from University College Dublin, Ireland and completed his PhD on “Proteolysis in Apoptosis” at the Queensland Institute for Medical Research in Brisbane. He moved to San Diego in 1998 to work at the La Jolla Institute for Allergy and Immunology where he became interested in using microscopy and flow cytometry to unravel pathways that orchestrate cancer cell death. He returned to Australia as Peter Doherty Fellow to work at the Peter MacCallum Cancer Centre on understanding how cells of the immune system kill cancer cells. He continued this research and its application for treating leukemia and prostate cancer as an NHMRC CDA fellow and an ARC Futures Fellow at the Mater Medical Research Institute and the Translational Research Institute in Brisbane. In 2012 he moved back to the QIMR Berghofer Medical Research Institute to help set up the Australian Cancer Research Foundation-Centre for Comprehensive Biomedical Imaging as part of the Flow Cytometry and Imaging Facility. Nigel has published more than 80 original manuscripts that have been cited more than 6500 times, including a recent compendium of 14 flow cytometry and imaging protocols for studying cell death in Cold Spring Harbour Press.
QIMR Berghofer Medical Research Institute
During Maria Rebelo’s PhD in Parasitology, she developed a novel assay drug based on the flow cytometric detection of haemozoin to assess antimalarial drug effects. The method was developed using a rodent model of malaria, optimized with laboratory culture-adapted P. falciparum and then assessed in a 6-month trial in the field, in Gabon. For the first time, she was able to show that haemozoin inside parasitised erythrocytes could be detected by flow cytometry, and that their detection allowed to detect drug effects and drug resistance earlier (24 h) than by any other currently available drug assay (48 – 72 h). Dr Rebelo sought to further optimise this novel drug assay in the hope of making it available not only in well-equipped laboratories, but also in resource-limited settings. Working closely with Dr Howard M. Shapiro, Center for Microbial Cytometry in Boston, she aimed to develop simple, easy and affordable cytometers to be used in the field for malaria diagnosis and for drug testing. Later, she has also collaborated with Prof. Istavn Kezmarki, University of Budapest, where they validated a novel device to diagnose malaria by haemozoin detection.
Publications related to flow cytometry
- Rebelo M, Tempera C, Bispo C, Andrade C, Gardner R, Shapiro HM, Hänscheid T. Light depolarization measurements in malaria: A new job for an old friend. Cytometry A 2015; 87(5):437-45.
- Rebelo M, Tempera C, Fernandes JF, Grobusch MP, Hänscheid T. Assessing antimalarial drug effects ex vivo using the haemozoin detection assay. Malaria Jorunal 2015; 14:140.
- Rebelo M, Sousa C, Shapiro HM, Mota MM, Grobusch MP, Hanscheid T. A novel flow cytometric hemozoin detection assay for real-time sensitivity testing of Plasmodium falciparum. PlosOne 2013; 8(4):e61606.
- Rebelo M, Shapiro HM, Amaral T, Melo-Cristino J, Hänscheid T. Haemozoin detection in infected erythrocytes for P. falciparum malaria diagnosis – prospects and limitations. Acta Tropica 2012; 123(1):58-61.
- Frita R, Rebelo M, Pamplona A, Vigario AM, Mota MM, Grobusch MP, Hänscheid T. Simple flow cytometric detection of haemozoin containing leukocytes and erythrocytes for research on diagnosis, immunology and drug sensitivity testing. Malaria Journal 2011; 10:74.
University of Melbourne and Sir Peter MacCallum Department of Oncology
David Westerman is a University of Melbourne graduate with dual fellowships and has held his current position as Head of Haematopathology at Peter MacCallum Cancer Centre, since 2000. He is Deputy Director of the Dept of Pathology, Chair of the Transfusion Medicine Committee and holds honorary appointments with the University of Melbourne at St Vincent’s Hospital Clinical School, and the Sir Peter MacCallum Dept of Oncology. He is a member of the RCPA immunophenotpying committee. He has broad clinical and laboratory academic interests including teaching, flow cytometry, molecular haematology and biomarkers which are reflected by over 100 peer reviewed publications.
Department of Medicine, Cancer Research Center University of Salamanca
Alberto Orfao is currently Full Professor of the Department of Medicine and Scientific Director of both the General Cytometry Service and the Cell sorting Service at the University of Salamanca, the Spanish National DNA Bank (Ministry of Economy and Competitivity) and the Network of Tumor Biobanks of Castilla y Leon (Spain). His research activities are based on his position as one of the Principal Investigators at the Cancer Research Center of Salamanca and they are mainly focussed on the field of hematological malignancies and the relationship between the immune system and cancer. He has contributed to >620 publications and book chapters, being co-author of >535 scientific papers in international journals, with an overall h-index of 60 and more than 14,500 accumulated citations; in addition, he is inventor of 33 (granted/pending) patents. He has received over 40 awards and recognitions including the Berend Howen and the Wallace Coulter awards of the International Society for Laboratory Hematology and the International Society for Clinical Cytometry, respectively, and the 2012 Castilla and Leon Prize for Scientific and Technical Research. He is currently member of the external scientific committees of several research institutions in Brasil, Spain and other European countries, and he is member of multiple national and international scientific evaluation panels and groups, including the EuroFlow Consortium (co-chair), European Scientific Foundation for Laboratory Hemato-Oncology (ESLHO), the European Leukemia Net (ELN) and the TiMaScan Consortium. He is also member of the editorial board of several scientific journals, such as Leukemia, Human Genetics and Cytometry B.
Director of University of Washington Medicine's Hematopathology and SCCA Pathology laboratories
Brent Wood, M.D., Ph.D., is a board certified pathologist and director of UW Medicine's Hematopathology and SCCA Pathology laboratories and medical director of SCCA laboratories. He is also a UW professor of Laboratory Medicine, Clinical Laboratory Administration and Pathology. Dr. Wood’s role is to ensure UW Medicine laboratories provide the most accurate, appropriate, current, cost-effective and timely testing possible to patients and medical staff. His professional responsibilities include the clinical diagnosis of hematopoietic disease and teaching hematopathology to medical technology students, medical students, residents and fellows. Dr. Wood earned his M.D. at Loma Linda University. His laboratory serves as one of two national reference laboratories for the flow cytometric identification of minimal residual disease in childhood acute lymphoblastic leukemia for the Children’s Oncology Group. Dr. Wood lectures nationally and internationally on clinical applications of flow cytometry and is past president of the International Clinical Cytometry Society.
Becton Dickinson Immunocytometry Systems
John Wotherspoon pursued his interest in immunology as a research student at Sydney University where he completed both MSc and PhD studies in transplant immunology and graft rejection (1982-88). During this time, he established the first cell sorter platform at the Centre for Immunology. Practical experience in immunochemistry, fluorochrome conjugation, and antibody titration provided the foundation experience to support the development of staining and application protocols needed by research collaborators. In 1989, he took an opportunity to join the local team of BD Immunocytometry Systems, Australia, as Applications Specialist. Across the subsequent 28 years, mostly in Asia, he had roles of increasing responsibility to develop the flow cytometry business. Throughout this time, his focus was capability training and education in flow technologies to improve clinical and academic research studies. Key programmes supported were the ‘Good Laboratory Practice Resource’ to improve accurate and reliable CD4 testing in local laboratories supporting HIV patient care; and the BD Horizon Multicolour education workshops.
Asia-PacificAapplication Specialist, Cytek
With a background in Immunology, Edmund Chua started his work in A*STAR, Singapore where he developed an interest in human immunology. After his Masters, he started working as the Flow Core Manager for the Institute of Molecular and Cell Biology. He handled and worked on several translational immunology projects in human and non-human primate research within the institute and clinical trial programmes in Singapore, using different high dimensional flow cytometry systems. As Cytek’s asia-pacific application specialist, he has worked extensively with users from different research backgrounds to advance their work on Cytek’s spectral flow cytometer.
QIMR Berghofer Medical Research Institute
Amanda Stanley is an experienced flow cytometry analyst at QIMR Berghofer. Amanda has 20 years biomedical research experience with extensive expertise in both flow cytometry and imaging. Amanda completed her BSc (Hons) in Biological Sciences (1999) and her PhD (2003) at the University of Edinburgh. She then undertook postdoctoral research from 2003 - 2016 with Prof. Christian Engwerda (QIMR Berghofer), Prof. Jennifer Stow and Assoc. Prof. Kate Schroder (both at Institute for Molecular Bioscience, University of Queensland). Amanda’s research spans immunology and cell biology, describing immune mechanisms during infection, macrophage biology and inflammasome biology. Amanda moved back to QIMR Berghofer in 2016 to take up a position in the flow cytometry and imaging facility where she has been further developing her interests in flow cytometry applications and cell sorting. She has designed and optimised a number of high parameter multicolour panels for flow cytometry. She has also performed a significant body of work to characterise and optimise the different flow cytometers at QIMR Berghofer. Amanda has also developed interests in clinical flow cytometry and has managed and performed the flow cytometry component of a number of clinical trials within the facility. Amanda has previously held her own grant funding and has published 31 original manuscripts.
Becton Dickinson Biosciences
Robert Balderas has 40 years of leadership experience in both academia and the biotechnology industry. As a corporate scientist, site manager, and marketer in the field of biotechnology he has contributed to the field. Robert has championed multiple key successful product launches during his tenure at Pharmingen and BD Biosciences and is recognized for his success in creating collaborations with scientists to generate products that are relevant to our customers. His experience in academic medicine accompanied by his strategic approaches as the VP of Research and Development is reflected in increased efficiencies within the Clinical and Research product development programs, with oversight in the development of more than 4000 reagents. Dr. Balderas track record of business process improvements is based on his expertise obtained while working at The Scripps Research Institute in the labs of Frank Dixon and Argyrios Theofilopoulos, where he focused 18 years in the field of autoimmunity. He is known for his ability to motivate his technical staff, diagnosing impediments in product development programs, building his efforts and focused on both product execution and career development of his staff, as well as integrating functional programs across other business operations. Robert has held several key positions during his tenure at BDB, including, Director of Research Reagent Marketing, Site Manager BD Pharmingen and VP R&D (Research and Clinical Reagents. Today, as VP of Biological Sciences, he is focused on accelerating market adoption of new tools and technologies into the Life Science Community, as well as leading strategic, scientific collaborations for BD Biosciences. Robert has been the architect and pioneer of the BD Horizon and the Biology and Technology Champion of the BD FACSymphony Platform. In addition his scientific experiences, Robert also received an MBA from the University of San Diego. Additionally, Robert also serves on the editorial board of Clinical Proteomics, has been involved with several business acquisitions, led two industrial/academic initiatives with CANVAC and the NCI, a board member on the HCMD Council (Human Cell Differentiation Molecule), a member of the UCSD Industrial Liaison Program, a member of the Deans Council for the UCSD School of Biological Sciences, a Board Member of FOCIS, SAB Member of Inflamex in Paris, a board member of the Oz Single Cell Consortium, a corporate member of the UCSD Jacobs School of Engineering and leads our BDB TLDP Recruiting Team for the BD Biosciences. He has shared in publishing over 75 scientific journal articles, and is a recipient of 2 BD Howe Award for “Sensing, Sourcing and Seeking New Technologies and for the Advancement of Technologies for Product Success”.
Howard Shapiro Laboratories
Howard Shapiro received his B. A. in Biochemical Sciences from Harvard in 1961 and his M. D. from New York University in 1965. Although he has had clinical training in surgery and medical oncology, he has spent most of his career developing cytometric instrumentation and methodology. While at NIH in the late 1960's, he and colleagues developed the first interactive compterized optical microscope system. Working at various Boston-area institutions since 1975, he has built and worked with both large and complex and small and simpler flow cytometers, focusing on studies of lymphocyte activation and bacterial and parasite physiology and response to drugs. Most recently, he has developed a new generation of simple and inexpensive fluorescence image cytometers intended for diagnostic applications to malaria, TB, and HIV/AIDS in resource-poor countries. He is the author of a widely used textbook, Practical Flow Cytometry (4th Edition, John Wiley and Sons, 2003), the full text of which can be downloaded without charge at https://www.beckman.com/resources/reading-material/ebooks/practical-flow-cytometry .
Kathryn Friend is National Sales Manager - Australia for Biolegend.
More details soon.
QIMR Berghofer Medical Research Institute
Paula completed her BSc at the University of Queensland and worked in university research and hospital diagnostic laboratories before joining the flow cytometry facility at QIMRBerghofer in 1996. Paula has extensive experience in multi parameter flow cytometry, setting up complex multi color experiments for users of the core facility. She also has wide experience in running various types of bead based Immunoassays. Paula plays a major role in providing high quality cell sorting services, including rare cell and single cell sorting and liaising with users to optimise sort outcomes. Paula has a particular interest in education and has taken on the role of training new users of the facility.
QIMR Berghofer Medical Research Institute and Royal Brisbane and Women’s Hospital
Siok is a clinician scientist. She is a senior research fellow at QIMR Berghofer where she heads the Translational Cancer Immunotherapy Laboratory. She is also a clinical haematologist and bone marrow transplant physician at the Royal Brisbane and Women’s Hospital. Dr Tey graduated from the University of Queensland in 1996 and completed her training in clinical and laboratory haematology in Brisbane in 2005. This was followed by a 2-year research fellowship at the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, USA. There, she developed a clinically applicable strategy to genetically modify T cells to make them delete-able in the setting of adverse events, and took this to a successful first-in-human clinical trial. She returned to Brisbane in 2007 and took up a staff specialist position at Royal Brisbane and Women’s Hospital and undertook a PhD on cytomegalovirus immunity at QIMR Berghofer. She started her own laboratory in 2017. She was appointed Medical Director for Q-Gen Cell Therapeutics, which is the Good Manufacturing Practice (GMP) facility at QIMR Berghofer in 2018. Dr Tey’s research interest are in developing and delivering novel cell and gene therapy in the context of cancer immunotherapy and bone marrow transplantation. In 2014, she opened the first clinical trial in Queensland to use genetically engineered cells, and established within QIMR Berghofer the capacity to manufacture gene-modified cells for clinical trials. She is now working on using regulatory T cells to treat graft-versus-host disease, using clinical grade FACS sorting to obtain regulatory T cells in high purity. Her research has been published in New England Journal of Medicine, Science, Science Immunology, Lancet Oncology, Clinical Cancer Research, Blood and others.
QIMR Berghofer Medical Research Institute
Michael has been involved with flow cytometry since 1995. After completing of his PhD (trafficking of antigen presenting cells in cutaneous carcinogenesis), Michael completed Postdoc’s at the University of Queensland School of Medicine using flow cytometry to study defective T cell responses in Multiple Sclerosis and at QIMR Berghofer immune responses to human cytomegalovirus. He managed the flow cytometry facility for the University of Queensland Diamantina Institute, before moving to QIMR Berghofer in 2013 where he provides high speed cell sorting expertise, problem solving the facilities cytometers and providing technical advice to facility users. Michael’s high technical expertise and attention to detail with the ability to repair faults and modify equipment to meet our users requirements is a great asset to QIMR Berghofer.
QIMR Berghofer Medical Research Institute
Allison earned her PhD in Biological Oceanography from Texas A&M University and first came to Australia as an NSF/AAS fellow at UWA. She has done two post docs at UWA and UTS focused on the role marine microbes play in global carbon and nitrogen cycling. Throughout, she has used flow cytometry to enumerate and classify marine microbes. She has developed and optimised multiple flow cytometric techniques to probe the function of environmental microbial populations and has sorted living populations at sea for live cell experimentation. Her role at QIMR Berghofer is assisting researchers with general flow cytometry applications and cell sorts (single cells or populations). Her extensive expertise in microbial flow is an asset to our lab as microbiome studies become more popular.
QIMR Berghofer Medical Research Institute
Tobias completed his Diploma (M.Sc. equivalent) in Biomedical Science at Bonn University, Germany (2010), followed by a PhD in cancer immunology with Prof. Thomas Tueting at Bonn University, Germany (2015). After a short post-doctoral training at the Otto-van Guerike University Magdeburg, he was awarded the prestigious EMBO Long-term Fellowship Award. Subsequently, he moved to Brisbane, Australia to join the laboratory of Prof. Mark Smyth at the QIMR Berghofer Medical Research Institute. During his post-doctoral training Tobias studied the impact of neutrophils on cancer immunotherapy and the role of NK cells and innate lymphoid cells for tumor development and progression. In 2018, he has been appointed a Team Head in the Department of Immunology at QIMR Berghofer Medical Research Institute. Tobias has over 10 year’s experience in multi-colour flow cytometry and cells sorting of immune cells in the context of cancer. Recently, Tobias has developed flow panels on the Cytek Aurora to characterize rare populations of innate lymphoid cells in the tumor microenvironment.